[1] Vial P A, Ferrés M, Vial C, et al.Hantavirus in humans: a review of clinical aspects and management[J]. Lancet Infect Dis, 2023, 23(9):e371-e382. [2] Harris G H, Sinchi A, Lawler J, et al.Andes Virus - A Clinical Review[J]. N Engl J Med. 2026. [3] Hertelendy A J, Gostin L O, Ciottone G R.The MV Hondius Hantavirus Outbreak-Lessons for Pandemic Preparedness[J]. JAMA, 2026, 336(3):193-195. [4] Kupferschmidt K.Cruise ship outbreak spotlights a little-studied hantavirus[J]. Science. 2026, 392(6799):672-673. [5] Toledo J, Haby M M, Reveiz L, et al.Evidence for Human-to-Human Transmission of Hantavirus: A Systematic Review[J]. J Infect Dis, 2022,226(8):1362-1371. [6] Islam M S, Chughtai A A, Wood J G, et al.Hantavirus outbreak on a cruise ship in the South Atlantic[J]. Lancet, 2026,407(10545):2286-2287. [7] World Health Organization. Hantavirus outbreak linked to cruise ship travel,Multi-locations[EB/OL]. (2026-07-02)[2026-08-09]. https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON611. [8] Centers for Disease Control and Prevention. About Hantavirus[EB/OL]. (2026-05-09)[2026-08-09]. https://www.cdc.gov/hantavirus/about/index.html. [9] Andes Virus Outbreak Working Group. Andes Hantavirus Outbreak on a Cruise Ship, 2026[J]. N Engl J Med, 2026, 394(24):2477-2479. [10] World Health Organization. Management of contacts of Andes virus (ANDV) cases from the MV Hondius cruise ship[EB/OL]. (2026-05-17)[2026-08-09]. https://www.who.int/publications/m/item/management-of-contacts-of-andes-virus-%28andv%29-cases-fromthe-mv-hondius-cruise-ship. [11] Taylor S L, Schmaljohn C S, Williams E P, et al.Pathogenicity and virulence of Rodent-Borne Orthohantaviruses[J]. Virulence. 2025, 16(1):2553784. [12] Parvate A, Williams E P, Taylor M K, et al.Diverse Morphology and Structural Features of Old and New World Hantaviruses[J]. Viruses, 2019, 11(9):862. [13] Jangra R K, Herbert A S, Li R, et al.Protocadherin-1 is essential for cell entry by New World hantaviruses[J]. Nature, 2018,563(7732):559-563. [14] Vaheri A, Strandin T, Hepojoki J, et al.Uncovering the mysteries of hantavirus infections[J]. Nat Rev Microbiol, 2013,11(8):539-550. [15] Paludan S R, Cherry S.Hantavirus disease and the need for pathogenesis-guided therapy[J]. J Exp Med, 2026, 223(7):e20260871. [16] Gavrilovskaya I N, Gorbunova E E, Mackow N A, et al.Hantaviruses direct endothelial cell permeability by sensitizing cells to the vascular permeability factor VEGF, while angiopoietin 1 and sphingosine 1-phosphate inhibit hantavirus-directed permeability[J]. J Virol, 2008, 82(12):5797-5806. [17] Sane J, Laine O, Mäkelä S, et al.Complement activation in Puumala hantavirus infection correlates with disease severity[J]. Ann Med, 2012,44(5):468-475. [18] Sironen T, Sane J, Lokki M L, et al. Fatal Puumala Hantavirus Disease: Involvement of Complement Activation and Vascular Leakage in the Pathobiology[J]. Open Forum Infect Dis, 2017,4(4):ofx229. [19] Centers for Disease Control and Prevention. Interim Guidance for Public Health Assessment and Management of People with Potential Exposure to Andes Virus[EB/OL]. (2026-07-07)[2026-08-09]. https://archive.cdc.gov/www_cdc_gov/hantavirus/php/emergency-guidance/index.html. [20] Mitjà O.Andes virus on a cruise ship: person-to-person transmission and an empty pipeline[J]. Lancet Infect Dis. 2026,26(7):e271-e272. [21] Dryden M, Blumberg L, Weyer J, et al.Cruise ship hantavirus outbreak in remote island communities[J]. Lancet, 2026,407(10545):2285-2286. [22] Sehgal A, Mehta S, Sahay K, et al.Hemorrhagic Fever with Renal Syndrome in Asia: History, Pathogenesis, Diagnosis, Treatment, and Prevention[J]. Viruses, 2023,15(2):561. [23] Ferrés M, Martínez-Valdebenito C, Henriquez C, et al.Viral shedding and viraemia of Andes virus during acute hantavirus infection: a prospective study[J]. Lancet Infect Dis, 2024,24(7):775-782. [24] Ferrés M, Vial P, Marco C, et al.Prospective evaluation of household contacts of persons with hantavirus cardiopulmonary syndrome in chile[J]. J Infect Dis, 2007, 195(11):1563-1571. [25] World Health Organization.Laboratory testing of Andes virus (Orthohantavirus andesense) infection: Interim guidance. Geneva: World Health Organization; 2026. (WHO Guidelines Approved by the Guidelines Review Committee). [26] Galeno H, Mora J, Villagra E, et al.First human isolate of Hantavirus (Andes virus) in the Americas[J]. Emerg Infect Dis, 2002, 8(7):657-661. [27] Chediack V, Calvo M, Cunto E, et al.Hantavirus infection: A narrative review focusing on epidemiology, diagnosis, infection control and treatment in the era of globalisation[J]. Med Intensiva (Engl Ed), 2026:502523 [28] Fama F, Molà F, Rizzo A, et al.Andes virus-associated cardiopulmonary syndrome: diagnostic approaches, clinical management, and evidence gaps-a scoping review[J]. Clin Microbiol Infect, 2026. [29] Dietl C A, Wernly J A, Pett S B, et al.Extracorporeal membrane oxygenation support improves survival of patients with severe Hantavirus cardiopulmonary syndrome[J]. J Thorac Cardiovasc Surg, 2008, 135(3):579-584. [30] Safronetz D, Haddock E, Feldmann F, et al.In vitro and in vivo activity of ribavirin against Andes virus infection[J]. PLoS One. 2011,6(8):e23560. [31] Vial P A, Valdivieso F, Ferres M, et al.High-dose intravenous methylprednisolone for hantavirus cardiopulmonary syndrome in Chile: a double-blind, randomized controlled clinical trial[J]. Clin Infect Dis, 2013, 57(7):943-951. [32] Miriam E, Sacristán S, Tatiana M F, et al.First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib[J]. Clin Microbiol Infect, 2026, 32(8):1360-1366. [33] Vial P A, Valdivieso F, Calvo M, et al.A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by Andes virus[J]. Antivir Ther, 2015,20(4):377-386. [34] Torres-Pérez F, Palma R E, Hjelle B, et al.Andes virus infections in the rodent reservoir and in humans vary across contrasting landscapes in Chile[J]. Infect Genet Evol, 2010, 10(6):820-825. [35] Khalil H, Hörnfeldt B, Evander M, et al.Dynamics and drivers of hantavirus prevalence in rodent populations[J]. Vector Borne Zoonotic Dis, 2014, 14(8):537-551. [36] Jonsson C B, Figueiredo L T, Vapalahti O.A global perspective on hantavirus ecology, epidemiology, and disease[J]. Clin Microbiol Rev, 2010, 23(2):412-441. [37] Wells R M, Sosa Estani S, Yadon Z E, et al.An unusual hantavirus outbreak in southern Argentina: person-to-person transmission? Hantavirus Pulmonary Syndrome Study Group for Patagonia[J]. Emerg Infect Dis, 1997, 3(2):171-174. [38] Martínez V P, Di Paola N, Alonso D O, et al."Super-Spreaders" and Person-to-Person Transmission of Andes Virus in Argentina[J]. N Engl J Med, 2020, 383(23):2230-2241. [39] Bogacka A, Pupaibool J, Genderen P J J, et al. An Unexpected Outbreak at Sea: Revisiting Hantavirus Transmission Dynamics[J]. J Travel Med, 2026. [40] World Health Organization. WHO Technical note for the disembarkation and onward management of passengers and crew in the context of an Andes virus-associated cluster MV Hondius cruise ship[EB/OL]. (2026-05-10)[2026-08-09]. https://www.who.int/publications/m/item/who-technical-note-for-the-disembarkation-and-onward-management-of-passengers-and-crew-in-the-context-of-an-andes-virus-associated-cluster-mv-hondius-cruise-ship. [41] World Health Organization. International Health Regulations (2005). 3rd ed. Geneva: World Health Organization; 2016. |